EvolveImmune Therapeutics
Hemachander Capiralla has a diverse work experience spanning over two decades. Hemachander is currently working as a Principal Scientist at EvolveImmune Therapeutics since March 2023. Previously, they held the position of Senior Scientist, Immune Modulation at Boehringer Ingelheim from November 2017 to March 2023. Prior to that, they worked as a Scientist at Boehringer Ingelheim from 2012 to 2017. Hemachander also served as a Postdoctoral Fellow on Alzheimer Research at Einstein Healthcare Network from 2008 to 2012, and as a Research Associate at Albert Einstein College of Medicine from 2003 to 2007. Hemachander gained international experience through a Post-doctoral Fellowship at the Center for Marine Biotechnology, University of Maryland from 2002 to 2003, and a Japanese Science and Technology fellowship at Kanagawa Industrial Technology Research Institute from 2000 to 2002.
Hemachander Capiralla received their Ph.D in Biotechnology from the University of Madras, completing their studies from 1993 to 1999.
This person is not in any offices
EvolveImmune Therapeutics
2 followers
EvolveImmune Therapeutics is a next-generation immunotherapy platform company based in Farmington and Branford, CT. Building upon research that originates from the Sidi Chen Lab at Yale University, EvolveImmune is leveraging a novel in vivo target discovery platform to develop a broad portfolio of first-in-class molecules for unmet needs in oncology and autoimmune diseases.